ANNUAL REPORT 2014

SAMUEL WAXMAN
CANCER RESEARCH FOUNDATION

ANNUAL REPORT 2014

The Samuel Waxman Cancer Research Foundation is an international organization dedicated to curing and preventing cancer. The Foundation is a pioneer in cancer research, focusing on uncovering the causes of cancer and reprogramming cancer cells. Our mission is to eradicate cancer by funding cutting-edge research that identifies and corrects abnormal gene function that causes cancer and develops minimally toxic treatments for patients.

Through our collaborative group of world-class scientists, the Institute Without Walls, investigators share information and tools to speed the pace of cancer research. Since our inception in 1976, The Foundation has awarded more than $85 million to support the work of more than 200 researchers across the globe.

OUR VISION

Dear friend,

Collaboration isn't what it used to be. It's better.

After 39 years of funding cutting-edge research by the brightest minds in cancer research, the Samuel Waxman Cancer Research Foundation (SWCRF) is proud to witness a landscape of research transformed by the model of collaboration we pioneered in 1976. Exciting new cancer therapies are emerging more frequently these days, powered by advances in technology and the quickened pace of investigation facilitated by information sharing.

SWCRF researchers are leading the way in bringing innovative treatments from the laboratory to the patient thanks to the support of our dedicated donors. The past year has seen promising clinical trials initiated for therapies developed by SWCRF investigators in a range of cancers. Researchers at Salk Institute, led by Ronald Evans, Ph.D., found that a synthetic derivative of vitamin D collapses the barrier of cells shielding pancreatic tumors, making them more susceptible to drugs and teamed up with the University of Pennsylvania on a trial testing the therapy in pancreatic cancer patients.

At Johns Hopkins University, our funded team of Stephen Baylin, M.D., Robert Casero, Ph.D., and Cynthia Zahnow, Ph.D., discovered genes that may predict tumors that evade detection from the immune system. Their discovery produced a clinical trial in lung cancer. Most recently, a trial conducted at Memorial Sloan Kettering Cancer Center showed promising results for a drug that targets a mutated enzyme that provokes AML. The therapy, based on the work of SWCRF researcher Ross Levine, M.D., corrects the genetic programming of AML cells much like the groundbreaking combination therapy developed by the SWCRF with the Shanghai Institute of Hematology that reprogrammed APL cells and remains the standard of treatment for this disease.

Although we are encouraged by these developments, we're hardly resting on our laurels. As part of our continued efforts to cure cancer through collaboration, we're augmenting our core categories of research funding with Aging & Cancer, a program that applies epigenetics to the investigation of the causes and effects of cancer in people over 50. Much of our currently funded research is applicable to this category and can lead to potential treatments for leukemia, prostate cancer and breast cancer.

You'll be hearing more about this exciting new initiative in the months ahead. We once again thank you for your continued support of our winning team of cancer researchers.

Sincerely,

Michael Nierenberg
Chairman



Samuel Waxman, M.D.
Founder and CEO

Robert Kantor
President

MICHAEL NIERENBERG

SAMUEL WAXMAN, M.D.

ROBERT KANTOR

YEAR IN REVIEW

MAY 6

On May 6, New York City's most prominent and philanthropic women supported the SWCRF's inaugural Ladies Who Lunch for a Cure benefit, which featured a fashion presentation by honoree Nicole Miller.

JULY 26

The SWCRF raised $400,000 for cancer research at the tenth annual A Hamptons Happening on July 26, which honored chef David Burke, Betsey Johnson and Paul Ridley.

NOV 13

The SWCRF relaunched its young professionals group, the Millennial Society, at an after-work mixer at the Empire Hotel on November 13.

MAY 12

The SWCRF honored Kenneth Anderson of Dana-Farber Cancer Institute and noted advocate Musa Mayer at its scientific symposium at Mount Sinai on May 12.

JULY 26

A Hamptons Happening honoree Betsey Johnson.

DEC 4

The 17th annual Collaborating for a Cure Gala raised $2.5 million for cancer research on December 4 at Cipriani Wall Street. The honorees were designers Cushnie et Ochs.

JULY 10

Philanthropic golfers congregated at the beautiful Creek Club in Locust Valley, NY on July 10 for the 32nd annual SWCRF golf tournament and dinner.

OCT 1 - OCT 31

Fashion designer Tadashi Shoji created a limited edition scarf as the centerpiece of his Pay it Forward fundraiser for SWCRF's breast cancer research programs in October.

DEC 4

Reggae star Ziggy Marley performed at the Waxman Gala.

PROOF OF PRINCIPLE

Blood Cancer Breakthroughs Spotlight the SWCRF's Pioneering Strategy of Reprogramming Cancer Cells.

The field of cancer research is buzzing about something that the Samuel Waxman Cancer Research Foundation (SWCRF) has known for more than 30 years --- cancer cells don't need to be destroyed when they can be reprogrammed to behave normally. Recent therapeutic innovations in leukemia are showing that the approach has great potential for changing how researchers tackle solving the puzzle that is cancer.

A recent article in *The New Yorker* detailed the promising results of a clinical trial conducted at Memorial Sloan Kettering Cancer Center for a new drug to treat acute myeloid leukemia (AML). The article, aptly titled The Transformation, traced the genesis of the drug, which targets a mutated enzyme called IDH-2 that creates a molecule that alters a cell's genetic programming by switching off certain genes in the cell so it doesn't mature. The cell multiplies wildly, resulting in AML. The treatment binds to the mutated enzyme and heads off the creation of the disruptive molecule, thereby allowing the cells to mature normally.

DRS. ZHEN-YI WANG, SAMUEL WAXMAN AND ZHU CHEN

The article's author, noted health care writer Dr. Jerome Groopman, likened this reprogramming of the cancer cell to the application of all-transretinoic acid (ATRA), a derivative of Vitamin A, to activate maturation of acute promyelocytic leukemia (APL) cells in the mid-1980s. This breakthrough therapy resulted from the research of Drs. Zhen-Yi Wang and Zhu Chen, working at Ruijin Hospital in Shanghai in collaboration with SWCRF founder and CEO Samuel Waxman, M.D., at Mount Sinai in New York City. Drs. Wang and Chen, who founded the Shanghai Institute of Hematology in 1987, published findings regarding a 1988 trial for ATRA in which 23 out of 24 APL patients went into remission. When patients experienced recurrence after treatment, the trio of researchers applied combination therapy to their strategy by adding arsenic trioxide as a secondary therapy, effectively curing the APL with a two-step process whereby the ATRA caused maturation of the leukemic cells and the arsenic trioxide led the cancer cells to self destruct through a process called apoptosis. This therapeutic approach increased the five-year survival rate for APL from 25 percent to 95 percent and remains the standard for treating the disease.

Although the AML drug and the APL therapy address different targets – the AML therapy heads off a mutated enzyme while the APL breakthrough treats a destructive hybrid protein --- their shared goal is changing cell behavior. The work of Dr. Ross Levine, a renowned expert in myeloid malignancies at Memorial Sloan Kettering Cancer Center and an SWCRF-funded researcher, laid the groundwork for the AML trial. Dr. Levine's research examines the genetic basis of myeloid malignancies, with a specific focus on the role of dysregulated signaling and disordered epigenetic patterning in myeloid leukemogenesis and in therapeutic response. His team's study of the role of mutations in the epigenetic modifiers in the transformation of blood cells helped bring the AML treatment from bench to bedside.

DR. ROSS LEVINE

"The support from the SWCRF has allowed us to make new insights into the pathogenesis of TET2/IDH-mutant leukemias, and to perform preclinical studies of novel therapeutics which target DNA methylation and mutant IDH proteins which are now entering the clinic," said Dr. Levine. "We are very excited by these results and grateful for the support. Moreover, the SWCRF's Institute Without Walls has provided an exceptional collaborative network which allows us to rapidly progress our work and to collaborate to achieve biologic and clinical impact."

Mutations and epigenetics are the key targets for investigation in Aging & Cancer, the SWCRF's new research initiative examining cancer incidence among people over the age of 50. A recent article in *The New York Times* reported that strides in the treatment of heart illnesses have increased the probability of more people between 55 and 84 dying of cancer than heart disease. Although age-related cancer diagnoses occur most frequently after the age of 60, cancer-causing cellular

mutations provoked by genetic and environmental factors can begin at 50 and build up over time. Current SWCRF-funded work relating to inflammation, stem cells and blood malignancies holds promise for new discoveries that can bring non-toxic therapies to this underserved population.

The Aging & Cancer program should benefit from a new collaboration between Israel and China that will examine the roles of two proteins in the onset of AML, the most common acute leukemia affecting adults whose incidence increases with age. Shai Izraeli, M.D., Sheba Medical Center at Tel Aviv University, and Sai-Juan Chen, M.D., Ph.D., the Shanghai of Hematology, both longtime funded SWCRF researchers, will serve as principal investigators in new research coordinated through a partnership between the Natural Science Foundation of China and the Israel Science Foundation and funded by the Chinese and Israeli governments. Drs. Izraeli and Chen aim to better understand the dynamics of transcription factors in the formation of AML.

"It's very exciting to see SWCRF collaborators making strides around the world with their transformative work," said SWCRF founder and CEO Samuel Waxman, M.D. "Our funded researchers are driving innovation in blood cancer investigation and their work is being recognized as leading science that is bringing us closer to a cancer cure."

FROM BENCH TO BEDSIDE

MARTIN S. TALLMAN, M.D.
Chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center, reflects on the impact of research on patient outcomes.

It is every cancer researcher's goal to see their theories lead to effective patient therapies and Memorial Sloan Kettering's recent clinical trial for an AML drug showed promising results. What were the findings?

In patients who had, in general, relapsed or refractory disease that had failed other more conventional therapies and had few options, a significant percent of them achieved a true, complete remission and many achieved a near complete remission. I know of several patients who achieved another remission with outpatient, oral drug therapy that was not very toxic and were able to go on to a transplant. This trial was a Phase 1 trial to find the optimal dose but we saw complete remissions very early, which was really striking and unusual in a Phase 1 trial. The next series of trials will be to combine this drug with intensive chemotherapy.

What is the demographic profile of the participants in the trial?

These were patients with quite advanced hematologic malignancies who had been treated with more conventional cytotoxic therapies and had failed to respond or had relapsed. About 20 percent had undergone transplants. Some had relapsed after transplants and some relapsed after six months of chemotherapy. There were roughly an equal number of men and women ranging between the ages of 33 and 90 with the average age being 67.

This trial parallels Dr. Waxman's differentiation of APL cells by combining ATRA with arsenic trioxide in collaboration with the Shanghai Institute of Hematology. How do you view the impact of this breakthrough on cancer research through the years?

When you think about the way we treat leukemia today, in a way it's not very elegant. We administer very intensive chemotherapy that is not able to distinguish between leukemia cells from healthy cells and kills every cell. We hope that the patient doesn't suffer significant toxicities and wait for healthy blood cells to reestablish normal blood formation. But Dr. Waxman and his colleagues at the Shanghai Institute of Hematology identified the method of differentiation; instead of killing the malignant cells, the approach turned them into healthy, mature cells. It was a remarkable advance, a seminal observation in the therapy of hematological malignancies and we think this new therapy is similar and that the differentiation is an identical mechanism, which is why it worked so well.

The SWCRF is proud that the work of its funded researcher Dr. Ross Levine played a central role in this breakthrough. As someone on the front line of patient care, how would you describe the impact of foundation support for science today?

I think it's absolutely critical. In acute and chronic leukemias, lymphoma and multiple myeloma, there has never been a time when so many more important discoveries are being made that are finally translating into improved outcomes and cures for patients. I think support from the Samuel Waxman Cancer Research Foundation and all foundations is critical if we're going to continue to make important discoveries that we can translate from the laboratory to the clinic. We have so many drugs and combinations to test it's mind-boggling. Ultimately, it's the most exciting time in medicine not just for us but also for patients so this funding has never been more important.

SUPPORT SYSTEM

Donations to the Samuel Waxman Cancer Research Foundation advance the work of the leading researchers collaborating within the SWCRF Institute Without Walls. Every day, our funded investigators make progress that helps science to better understand how cancer works and brings us closer to a cure.

CHRISTOPHER FRENCH, M.D.
BRIGHAM AND WOMEN'S HOSPITAL

INVESTING IN HOPE FOR A DEADLY CANCER

"We have had the fortune to be funded by the SWCRF for the past five years. The SWCRF has allowed us to focus particularly on the treatment of one of the most aggressive malignancies known, called NUT midline carcinoma (NMC), a rare subtype of squamous cell cancer. The SWCRF has nurtured our small program that began with no treatment for this horrible disease, to now three clinical trials in North America using targeted inhibitors of the causative cancer protein, called BRD4-NUT. Now this disease, which promised a median survival of 6.5 months, has some hope of a more effective treatment. Although most foundations might be disinterested in a rare disease such as this, the SWCRF had the insight to realize that NMC really is the exception that has proved the rule for many other common cancer types. It turns out that the BRD4 part of the cancer protein in NMC also drives cancers such as leukemia and prostate cancer, and thus the inhibitors that have opened the door to targeted therapy of NMC are also potentially useful in these much more common diseases. We have the forward-thinking Dr. Samuel Waxman and the SWCRF team of world-class scientific advisors to thank for these steps forward in cancer treatment."

JAYANTA DEBNATH, M.D.
UNIVERSITY OF CALIFORNIA SAN FRANCISCO

TARGETING METASTASIS IN BREAST CANCER

My research focuses on how autophagy can be targeted to impede breast cancer progression and metastasis. Autophagy is a fundamental cellular recycling pathway (literally meaning "self-eating") used by cancer cells to survive and thrive in stressful environments. Recently, we made the surprising discovery that autophagy also promotes the ability of tumor cells to secrete molecules that promote invasion. These findings challenge the long-held dogma that autophagy works as a metabolic adaptation pathway in cancer cells. Our SWCRF grant has proven invaluable in supporting this project and novel idea. We have since pinpointed that stromal fibroblasts, normal cells residing within a solid tumor that are critical for cancer growth, exhibit high levels of autophagy-dependent secretion. Upon specifically inhibiting autophagy in stromal cells, breast cancer progression is profoundly blocked in living organisms, presumably by "short-circuiting" a small environment that can produce tumors. These new findings are poised to completely transform how oncologists should apply autophagy inhibitors in the clinic. We are now testing the prediction that stroma-rich breast cancers will be uniquely susceptible to anti-autophagy drugs (e.g., hydroxychloroquine). In addition, the SWCRF "Institute Without Walls" has fostered exciting collaborations investigating the effects of how autophagy directs tumor dormancy, a critical but poorly understood aspect of metastatic progression.

JOSEP M. LLOVET, M.D.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

TARGETING NEW THERAPIES FOR GENETIC MUTATIONS THAT CAUSE A DEADLY LIVER CANCER

Intrahepatic cholangiocarcinoma (iCCA) is an uncommon primary liver cancer with no accepted systemic therapy for patients whose tumors cannot be removed surgically. Thus, discovery of novel targets for therapies is a clear clinical unmet need. In this context we launched a comprehensive study by using cutting-edge technology with genome sequencing to search for novel targets amenable for molecular therapies. Our effort has been supported by the SWCRF since the beginning and we have established collaborations with academic centers in the United States and Europe. As a result, we have been able to propose a molecular classification of iCCA and to identify a novel oncogenic and targetable FGFR2 fusion, FGFR2-PPHLN1, and activating mutations in the ARAF oncogene. Our work supports translating our discoveries in the clinical arena by treating iCCA patients with FGFR2 fusion events with specific FGFR2 inhibitors. In addition, we established a landscape of druggable mutations of this tumor that are present in around 70 percent of iCCA patients and may benefit from targeted therapies. The funding received has given us the opportunity to stand at the front line in the fight against iCCA and significantly contribute to the genomic characterization and treatment of this deadly disease.

REUBEN SHAW, PH.D.
SALK INSTITUTE

IDENTIFYING GENETIC ENABLERS OF THE SPREAD OF CANCER

My experience with the SWCRF has been incredibly rewarding. Our lab has been focused on the intersection of how metabolism and cancer are connected, and using our newfound discoveries to identify novel therapeutic targets and approaches to attack different subsets of cancer. In particular, little is known about how the specific genes that go awry at the very beginning of tumor initiation end up dictating how quickly a tumor ends up metastasizing throughout the body. We have found this past year a new signaling pathway that triggers metastasis of tumor cells, in a subset of lung, melanoma, and endometrial cancers. By elucidating several steps of this pathway, we have identified new therapeutic targets and biomarkers for those patients bearing these specific gene mutations and alterations, which will speed testing these possibilities in clinical trials. By fostering collaboration among scientists and clinicians across the world, the SWCRF has spurred novel and risky research which is most often where profound breakthroughs arise.

BLOOD MALIGNANCIES

Ravi Bhatia, M.D., *UAB Comprehensive Cancer Center*
Brad Cairns, Ph.D., *University of Utah*
Sai-Juan Chen, M.D., Ph.D., *Shanghai Institute of Hematology*
John D. Crispino, Ph.D., *Northwestern University*
Margaret Goodell, Ph.D., *Baylor College of Medicine*
Yongkui Jing, Ph.D., *Mount Sinai Medical Center*
David A. Jones, Ph.D., *University of Oklahoma*
Ross Levine, M.D., *Memorial Sloan Kettering*
Jonathan D. Licht, M.D., *Northwestern University*
Ari Melnick, M.D., *Weill Cornell Medical Center*
Warren Pear, M.D., Ph.D., *University of Pennsylvania*
Ruibao Ren, M.D., Ph.D., *Brandeis University*
Samuel Waxman, M.D., *Mount Sinai Medical Center*
Arthur Zelent, Ph.D., *University of Miami*

BRAIN CANCER PROGRAM

Albert S. Baldwin, Jr., Ph.D., *University of North Carolina, Chapel Hill*
Mark Lemmon, Ph.D., *University of Pennsylvania*
Kevan Shokat, Ph.D., *University of California, San Francisco*
William Weiss, Ph.D., *University of California, San Francisco*

BREAST CANCER PROGRAM

Albert S. Baldwin, Jr., Ph.D., *University of North Carolina, Chapel Hill*
Stephen Baylin, M.D., *Johns Hopkins University*
Robert A. Casero, Ph.D., *Johns Hopkins University*
Jayanta Debnath, M.D., *University of California San Francisco*
Eduardo Farias, Ph.D., *Mount Sinai Medical Center*
Doris Germain, Ph.D., *Mount Sinai Medical Center*
Wilson Miller, M.D., *Jewish General Hospital*
Samuel Waxman, M.D., *Mount Sinai Medical Center*
Robert A. Weinberg, Ph.D., *Whitehead Institute for Biomedical Research*
Cynthia Zahnow, Ph.D., *Johns Hopkins University*
Arthur Zelent, Ph.D., *University of Miami*
Ming-Ming Zhou, Ph.D., *Mount Sinai Medical Center*

CANCER STEM CELL PROGRAM

Julio Aguirre-Ghiso, Ph.D., *Mount Sinai Medical Center*
Nabeel Bardeesy, Ph.D., *Massachusetts General Hospital*
Stephen Baylin, M.D., *Johns Hopkins University*
Ravi Bhatia, M.D., *UAB Comprehensive Cancer Center*
Robert A. Casero, Ph.D., *Johns Hopkins University*
Margaret Goodell, Ph.D., *Baylor College of Medicine*
Robert A. Weinberg, Ph.D., *Whitehead Institute for Biomedical Research*
Cynthia Zahnow, Ph.D., *Johns Hopkins University*

CHILDHOOD AND YOUNG ADULT CANCERS

Albert Baldwin, Jr., Ph.D., *University of North Carolina, Chapel Hill*
James E. Bradner, M.D., *Dana-Farber Cancer Institute*
John D. Crispino, Ph.D., *Northwestern University*
Christopher A. French, M.D., *Brigham and Women's Hospital*
Shai Izraeli, M.D., *Tel Aviv University*
Mark Lemmon, Ph.D., *University of Pennsylvania*
Yang Shi, Ph.D., *Boston Children's Hospital & Harvard Medical School*
Kevan Shokat, Ph.D., *University of California, San Francisco*
Erwin G. Van Meir, Ph.D., *Emory University School of Medicine*
William Weiss, M.D., Ph.D., *University of California, San Francisco*

COLON CANCER PROGRAM

Ronald Evans, Ph.D., *Salk Institute*
Reuben Shaw, Ph.D., *Salk Institute*
Brad Cairns, Ph.D., *University of Utah*
David A. Jones, Ph.D., *University of Oklahoma*

LIVER CANCER PROGRAM

Stephen Baylin, M.D., *Johns Hopkins University*
Josep M. Llovet, M.D., *Mount Sinai Medical Center*
Devanand Sarkar, M.B.B.S., Ph.D., *Virginia Commonwealth University*
Samuel Waxman, M.D., *Mount Sinai Medical Center*

LUNG CANCER PROGRAM

Duane Compton, Ph.D., *Dartmouth Medical School*
Ethan Dmitrovsky, M.D., *MD Anderson Cancer Center*

MOUNT SINAI MEDICAL CENTER - SWCRF LABORATORY (MSMC)

Julio Aguirre-Ghiso, Ph.D., *Mount Sinai Medical Center*
Eduardo Farias, Ph.D., *Mount Sinai Medical Center*
Doris Germain, Ph.D., *Mount Sinai Medical Center*
Yongkui Jing, M.D., *Mount Sinai Medical Center*
Boris Leibovitch, Ph.D., *Mount Sinai Medical Center*
Samuel Waxman, M.D., *Mount Sinai Medical Center*

DEVELOPING EPIGENETIC THERAPY

Stephen Baylin, M.D., *Johns Hopkins University*
Robert Casero, Ph.D., *Johns Hopkins University*
Sai-Juan Chen, Ph.D., *Shanghai Institute of Hematology*
John D. Crispino, M.D., *Northwestern University*
Ronald Evans, Ph.D., *Salk Institute*
Alan Friedman, M.D., *Johns Hopkins University*
Margaret Goodell, Ph.D., *Baylor College of Medicine*
Shai Izraeli, M.D., *Tel Aviv University*
Yongkui Jing, Ph.D., *Mount Sinai Medical Center*
Jonathan D. Licht, M.D., *Northwestern University*
Alexander MacKerell, Ph.D., *University of Maryland*
Ari Melnick, M.D., *Weill Cornell School of Medicine*
Wilson Miller, M.D., Ph.D., *Jewish General Hospital*
Gilbert Privé, Ph.D., *University of Toronto*
Ruibao Ren, M.D., Ph.D., *Brandeis University*
Samuel Waxman, M.D., *Mount Sinai Medical Center*
Yue Xiong, Ph.D., *University of North Carolina, Chapel Hill*
Arthur Zelent, Ph.D., *University of Miami*
Ming-Ming Zhou, Ph.D., *Mount Sinai Medical Center*

PANCREATIC CANCER PROGRAM

Nabeel Bardeesy, Ph.D., *Massachusetts General Hospital*
Gregory David, Ph.D., *NYU School of Medicine*

SIH/SWCRF CO-PI PROGRAM

Sai-Juan Chen, Ph.D., *Shanghai Institute of Hematology*
Zhu Chen, M.D., Ph.D., *Shanghai Institute of Hematology*

TUMOR DORMANCY PROGRAM

Julio Aguirre-Ghiso, Ph.D., *Mount Sinai Medical Center*
Emily Bernstein, Ph.D., *Mount Sinai Medical Center*
Eduardo Farias, Ph.D., *Mount Sinai Medical Center*

IN MEMORIAM

KATHY SARNA

The Samuel Waxman Cancer Research Foundation remembers Kathleen "Kathy" Sarna, our dear friend and longtime supporter who passed away in March after complications from surgery for a brain tumor. Kathy, who along with her sisters Jane Stanczuk and the late Lucille Montrony ran the Three Strohm Sisters Family Foundation, was a force to be reckoned with in the quest to fund cancer research. Whether organizing one of the foundation's popular fundraisers, tending to the daily needs of the organization or advocating for research though one-on-one interactions, Kathy could be counted on to get results. It is her tenacity, directness and unassuming charm for which she will be remembered. She overcame a challenging childhood to raise a loving family with her husband Richard Sarna, have a career in advertising, survive breast cancer and make an indelible mark in the search for a cancer cure. Growing up in the Greenpoint section of Brooklyn, Kathy was born the fourth child of Joseph and Mary Strohm. The Strohm siblings, including brothers Joe, Edward and Frank, lost their mother to tuberculosis and their father was killed in a workplace accident.

These tragedies required that they be separated and raised by various family members. As the years passed, Kathy and her siblings drifted apart but were brought together in the 1990s when it was discovered that she, Jane and Lucille all had breast cancer. The family rallied around them as the sisters beat their breast cancer and started their fundraising mission in 1999, raising more than one million dollars for research through their foundation, with much of it benefiting the work of the SWCRF in pediatric and breast cancer. We stand with the Sarna and Strohm families in mourning the loss of Kathy and remain dedicated to continuing her legacy of advocacy for cancer research in partnership with the Three Strohm Sisters Family Foundation.

EMILIO LAMA

The Samuel Waxman Cancer Research Foundation (SWCRF) remembers supporter E. Antonio Lama, a well-respected businessman and community leader in the Dominican Republic who passed away of lung cancer in December at the age of 69. Through hard work and determination, he built a diversified group of companies with interests in automotives, plastics and paint manufacturing, hospitality, finance, and real estate. His success, together with his humble and humorous style and philanthropic giving, earned him the respect and admiration of many.

He was always a very private person in all his contributions and in his personal life. Always present when help was needed, he would never hesitate for a good cause; however, he never had an interest in taking the credit. He created The Magna Foundation in 2007 in order to start contributing to society and sustainable development, through the business instead of in a private manner, a project that is being developed by his successors. Mr. Lama made several generous donations to the SWCRF through The Magna Foundation.

He was a loving father and husband, and his priority in life was always his family. He was a brave man and accepted every challenge life gave him with no fear, dignity and a positive attitude. This quality was confirmed by SWCRF Founder and CEO Samuel Waxman, M.D., who treated Mr. Lama in New York City. Mr. Lama is survived by his wife Doralise, to whom he was married for 40 years, and four children: a daughter, Paula, and three sons, Agustin Antonio, Antonio, and Jose Gabriel, who are working in the businesses he created, following his steps and legacy.

THANK YOU

The following donors have shared The Samuel Waxman Cancer Research Foundation's vision and belief in collaboration by generously funding the Foundation's Institute Without Walls in 2014.

$200,000+
Mr. and Mrs. Reuben Mark

$100,000-$199,999
Mr. and Mrs. Wesley Edens
Emerald Foundation, Inc.
Mr. and Mrs. Arminio Fraga
Mr. and Mrs. Michael B. Nierenberg
Ms. Mary Henry and Mr. Howard Rubin
The Skirball Foundation
Soros Fund Charitable Foundation
Bettina and Spencer Waxman

$50,000-$99,999
The Rose M. Badgeley Charitable Trust
Musa and Tom Mayer
Morgan Stanley
Three Strohm Sisters Family Foundation
Triple Negative Breast Cancer Research Foundation
Mr. and Mrs. Jeffrey Verschleiser

$20,000-$49,999
Access Securities
Anonymous
Bank of America
Jack and Florence Berlin Foundation
Mr. and Mrs. Christopher M. Callahan
Mr. and Mrs. Peter Cherasia
Laura and James DeMare
Dentons
Douglas Elliman Real Estate
Mr. and Mrs. Scott Eichel
Mr. and Mrs. Johan Eveland
Mr. and Mrs. Kenneth Fishel
Good Hill Partners
Mr. and Mrs. Steven Gordon
Mr. W. David Hinkelman
Mr. Adam Katz
Mr. and Mrs. Howard Kurz
Jay N. Levine and Tammy L. Levine Family Foundation, Inc.
Lily Pond Capital Management
Mr. Thomas Maxwell
Mr. and Mrs. Jeffrey Mayer
Mr. Matthew McQueen
Mr. and Mrs. Randal A. Nardone
Mr. and Mrs. Craig Overlander
Palm Bay International
Mr. Randy Reiff
Andrew Sabin Family Foundation
Mara and Baron Silverstein
Alan B. Slifka Foundation
Mr. and Mrs. Andrew Sloves
Mr. Nicholas P. Smith
Mr. and Mrs. Joseph G. Steffa, Jr.
Tadashi Shoji
Mr. and Mrs. Laurence Tarica
Titan Advisors, LLC
Tsai Fan Yu Foundation
Ms. Dena K. Weiner and Mr. David Rozenholc
Mr. Lawrence Wosskow

$10,000-$19,999
Barclays North America
Mr. and Mrs. John D. Brewer, Jr.
BTIG, LLC
Cantor Fitzgerald Relief Fund Administration
Mr. Brian Carosielli
Mr. and Mrs. Matthew R. Chasin
Mr. Brian Chin
Mr. Steven Choran
Dale and Peter Claman
Credit Suisse
Mark and Trish Davies
Mr. Thomas Durkin
Mr. Jesse Elhai
EverBank
Hilary and Joseph Feshbach
The Fridolin Foundation
Mr. and Mrs. Paul Friedman
The G & A Foundation
Ms. Giselle Gerson
Dr. Roger Gilbert
Goldman Sachs & Co.
Mr. Jeff Gravelle
Alyssa and Cliff Greenberg
Mr. Robert M. Grillo
Mr. and Mrs. Marshall Insley
Mr. Gary Jacob
Jefferies LLC
Mr. Bernard Kaminsky
Mr. and Mrs. Gershon Kekst
The Litwin Foundation
Mr. Leonard Litwin
M & T Bank
Mr. and Mrs. Thomas Marano
Mr. Michael Mazzei
MFA Financial Inc.
Mr. Martin Migliara
Nomura
Marci and Glenn Pere
Susan & Elihu Rose Foundation, Inc.
Mrs. Leah P. Sanzari
Ms. Amanda Schumacher
The Robert Sillins Family Foundation, Inc.
Mr. Charles Sorrentino
Mr. and Mrs. Richard Spitz
Mr. and Mrs. Alan L. Tyson
Mr. James C. Weakley and Ms. Maria T. Poli
Mr. and Mrs. Joshua B. Weintraub
Norman and Rosita Winston Foundation

$5,000-$9,999
Mr. and Mrs. Joseph Ades
Alston & Bird
Lawrence and Joan Altman
Arlotta Enterprises, Ltd.
Ms. Christine Arlotta and Mr. Mario Pecoraro
Mr. and Mrs. William Arnold
Mr. and Mrs. Frederick Boos
Mr. George K. Brommer, III
Mr. Michael Commaroto
Ms. Georgine Cunliffe
Ms. Barbara Digan-Zweig
Mr. and Mrs. Robert Eichler
Ms. Jayme Fagas and Mr. Paul Strauch
Mr. and Mrs. Robert Fishbein
Mr. Christopher Garvie
Ms. Jeanmarie Genirs and Mr. Paul Josling
The Marsha Lilien Gladstein Foundation
Hatteras Financial Corporation
Mr. Robert Hershy
Mr. Bobby Hotaling
JP Morgan
Ms. Suzanne Klein
Ms. Lisa Konsker
Mr. Geoffrey Kott
Connie and Harvey Krueger
Mr. Norman Levine
Mr. Alexander Libin
Mr. Seemant Menon
Dana and Michael Miller
Mr. and Mrs. Ira Nierenberg
Options Group
Park East Gynecology and Surgery, PC
Mr. William Procida
Mr. and Mrs. Robert J. Richter
Debbie and Gil Schwartzberg
Mr. Frank Y. Skibo
Iris and Michael Smith
Mr. and Mrs. Marc Spilker
Sun Capital Partners, Inc.
Mr. Steven L. Swarzman
Tiffany & Co.
Mr. and Mrs. Richard C. Volpe
Ruth Winkelman Wender Foundation

Mr. Mitchell Winter and Lisa Kassel
Jill and Bobby Zarin

$1,000-$4,999

Ms. Kathy L. Anderson
Anonymous
Ms. Selin Aran
Arent Fox, LLP
Mr. Zach Aronson
Mr. Max Baker
Ms. Marjorie Baldinger
Mr. and Mrs. Frederick W. Barney, Jr.
Penny and Steven Beberman
Mr. Michael Bebon
Mr. Ralph Bernstein
Mr. Jason Biegel
Biener Auto Group
Blue Slate, LLC
Mr. and Mrs. Jonathan W. Bonesteel
Mr. Tom Boran
Mr. Eric Brophy
Ms. Ema Brown
Mr. Harvey Brown
Michael and Ellen Brown
Bonnie and David Cantor
Charles Komar & Sons
Mr. and Mrs. Phil Cedar
Chelten House Products, Inc.
Daniel and Rhonda Chestler
Ms. Jisook Choi
City Of Hope
Amy and Scott Claman
Debbie and David Cohen
Marilyn and Sonny Cohn
Mr. Giles Colwell
Mr. Gavin Coman
Ms. Wynne Comer
Commonwealth Land Title Insurance Company
Mr. and Mrs. Thomas A. Conway
Mr. Edward Conway
Mr. Noah Cooper
Mr. James Cox
Mr. Martin L. Coyne
Mr. Ryan Craft
Cushman & Wakefield Inc.
Cushnie Et Ochs
Mr. Apurva Dabholkar
D.B.D. Contracting, LLC.
Mr. Gary DePersia
Mr. Conrad Dequadros
Mr. Jeffrey Desind
Ms. Rosalind Devon and Mr. Sanford Batkin
Kim and Jordan Dickstein
Mr. David Dietche
Dr. and Mrs. Ethan Dmitrovsky
Mr. Thomas J. Doherty
Ms. Adina Dolfman
Mr. Christopher M. Dowd
Mr. and Mrs. John Draghi
Mr. Ryan Driscoll
Dr. Susan D. Drossman and Mr. Adam Sokoloff
Glenn and Eva Dubin
Mr. Trent Duprey
The Dwight Group
Dynamic Credit Management
Mr. and Mrs. Jim Egan
Ms. Blake Eger
The Charles Evans Foundation
Mr. Timothy P. Fallon
Mr. Evan Federman
Mr. and Mrs. Robert Feidelson
Mr. James Finkel
Dori and Michael Fishbin
Mr. Christopher Flanagan
Mr. David Flannery
Fragrance Group
Mr. and Mrs. James E. Frankel
Mr. Daniel Frommer
Ms. Carol Fuller Venezia
Mr. Kevin Gately
Gess Donor Fund, A Donor Advised Fund of Combined Jewish Philanthropies of Greater Boston, Inc.
The Thomas and William Gilbane Foundation
Ms. Susan Givens
Ms. Cheryl Glory
Mr. and Mrs. Alan J. Goldberger
Laurie and Jeff Goldberger
Ms. Marjorie Goldin
Ms. Adrienne Gordon and Mr. Gary Herman
Greenwich Associates
Mr. Jeff Gropper
Ms. Felicia Grumet and Mr. Mitchell Levine
Ms. Martha Gunderson
Ms. Mary P. Haggerty
Mr. Joel C. Haims
The Stephen P. Hanson Family Foundation, Inc.
Mr. and Mrs. James Harrington
Haskell Jewels
Mr. and Mrs. Robert Hecht
Mr. Robert Heffner
Mr. and Mrs. Dennis A. Herman
Mr. and Mrs. Patrick Higgins
High Five Foundation
Hilldun
Mr. and Mrs. Daniel J. Hoffman
Mr. Michael Hokin
Mr. Vincent Horcasitos
Horizon Group
Mr. Michael Huang
Dana and Michael Hubbe
Ms. Marie Ianniello
Mr. and Mrs. Stuart Israel
Mr. Max K. Jaeger
Evan and Florence Janovic
Mr. Steven Jeraci
Mr. Charles Jin
JMP Securities
Ms. Betsey Johnson
Mr. William H. Johnston
Ms. Katherine Jones
Mr. Mike Joo
Mrs. Shanna Joseph
Mr. and Mrs. Kenneth Joseph
Ms. Nurit Kahane and Mr. Werner Haase
Mr. Ian Kahn
Mr. and Mrs. Edward Kaminsky
Mr. and Mrs. Robert Kantor
Ms. Mary Y. Kantor
Marc and Jodi Kaplan
Karuna Foundation
Deena and Erik Katz
Ms. Tracey Keegan
Mr. and Mrs. Steven Keltz
Sanjeev Khanna
Mrs. Sharon Wilkes Kinberg and Mr. Robert Kinberg
Mr. and Mrs. David J. Klein
Kleinberg, Kaplan, Wolff & Cohen, PC
Mr. Craig Knutson
Mr. Paul Kolaj
Mrs. Karyn Kornfeld
Mr. and Mrs. Andrew Kramer
Mr. and Mrs. Norman Kramer
Mr. and Mrs. Eric L. Kriftcher
Mr. Joseph La Delfa Jr.
Mr. and Mrs. Michael Labadorf
Mr. Carey F. Lathrop
Mr. and Mrs. Norman Lattman
David and Marcia Lavipour
Mr. and Mrs. Robert Lawrence
Dr. and Mrs. Albert M. Lefkovits
Mr. and Mrs. Eric Leinwand
Saul and Eleanor Lerner Foundation, Inc.
Les Chateaux
Ms. Janice T. Levites
Mr. Paul Levy
Dr. and Mrs. Jonathan D. Licht
Marilyn and Sam Linder
Mr. and Mrs. Avery Lipman
Mr. Cameron MacDougall
The David & Sondra Mack Foundation
Ms. Romy Malbin
Mr. and Mrs. Harvey Mallement
Mr. and Mrs. Satish M. Mansukhani
Mr. and Mrs. Frederick Marcus
Massachusetts General Hospital Cancer Center
Ms. Susan Maude

Mr. and Mrs. Steve Mayer
Mr. and Mrs. Charles McGuffog
Mr. Justin McNeilus
Media Storm, LLC
Mr. Craig M. Meltzer
Ellen and Rick Miller
Eve and Stephen Milstein
Mr. James W. Milton
Mission Capital
M'ODA 'OPERANDI
Mr. Peter Mondics
Ms. Pamela Morgan and Mr. Michael Trokel
Mr. and Mrs. Bob Munsey
Mr. and Mrs. Stephen J. Muto
Mr. and Mrs. Glenn Myles
Mr. and Mrs. Ari Nathan
Ms. Cynthia Neiditch
Neiman Marcus Group, Inc.
Mr. Jack N. Nuismer
Ms. Theresa O'Neill
Mr. Daniel J. Ordan
Mr. Michael Orecchio
Mr. and Mrs. Hensen Orser
Ms. Lauren Osborne
Mr. Duane Paddock
Paramount Beauty
Mr. and Mrs. Michael J. Pascarella
Pere360
Mr. and Mrs. Michael Petteruti
Mr. Jerome Pickholz
Mr. Darrin Pinkham
The Plaza Hotel
Jamie and Mark Pollack
Ms. Jen B. Press
William H. Prusoff Foundation
Mr. and Mrs. Salvatore L. Puliafico
Robin Pzena
Mr. Philip Radus
Mr. James T. Raezer
Amit Rametra
Ms. Rhonda Ramparas
Raymond James Financial
Mr. Richard Reda
Tade Reen
Ms. Rashaan Reid
Mr. Darren Reinstein
Mr. Nicholas Rentas
Ms. Milena G. Resca and
Mr. Tiziano Legnaro
Revman International
Mr. John Riconda
Ms. Christina Rose
Mr. Mark Rosen
Dr. and Mrs. Alan Rosenfeld
Mr. and Mrs. Louis Rosenfeld
Dr. and Mrs. Larry Rosenthal
Mr. and Mrs. Robert Rotanz
Lewis and Wendy Rubin
Dr. and Mrs. Steven Rubin
Alice and Michael Rudell
Mr. and Mrs. John Ryding
Mr. Benny Salerno
Mr. Phil Sarna
Mrs. Edwin C. Scheurer
Mr. Greg Schwab
Mr. John Schwartz
Schwartz & Company, LLP
Mr. Nicholas Seminara
Mr. John Semrai
Rapaport Shallat Foundation
Mr. and Mrs. Thomas Shea
Meryl and Ken Sherman
Dr. David M. Shipper
Mr. and Mrs. Howard Shlafmitz
Mr. and Mrs. Tony M. Shogren
Mr. Justin Short
Mr. and Mrs. Allen Siegel
Mr. Richard Sigg
Mr. Leon Silverman
Mr. Michael Simon
Ms. Kushmaotee Gujadhur and Mr. Gyan Sinha
Mr. Gary M. Slutsky
Mr. and Mrs. Walter Small
Mr. Adam Smith
Mr. Peter Smith
The Sobel Family Foundation
Mr. and Mrs. Michael Sokol
Solow Realty & Development Company LLC
South Coast Plaza
Mr. Michael Stavros
Ms. Diane Steiner
Steven Madden, Ltd.
Mr. Alex Stone
Ms. Mary Stone and Mr. Channing Creecy
Mr. Miles Stuchin
Mr. and Mrs. Jay Sullivan
The Tadashi Foundation
Ms. Cynthia Temple
Tenshore Realty
Mr. Marc J. Toscano
Tree of Life Foundation International
Ms. Wendy Ull
The Venable Foundation
Mr. Christopher Verrillo
Mr. Subramani Viswanathan
Mr. Christopher Walcott
Mr. Mike Wassong
Dr. and Mrs. Samuel Waxman
Mr. and Mrs. Scott Waxman
Waxman Leavell Literary Agency
WCBS
Weill Cornell Medical College
Ms. Adele Weiner
Mr. and Mrs. Stephen Weinstein
Mr. Andrew Weinstein
Wells Fargo
Mr. Aaron Welsh
Mr. and Mrs. Paul Whitman
Whitton-Spector Foundation
Richard and Debra Wilpon
Cindy and David Wittels
Dr. and Mrs. Richard A. Wolff
Mr. Adam Yarnold
The Janet Yaseen Foundation
Mr. Harry You

$500-$999

10th Street Chiropractic
All Star Security
Warren and Hayley Alstodt
Anita Wolfe Interiors
Judith and Alan Appelbaum
Bank of America United Way Campaign
Baum - Essex
Beachfront Property Management
Ms. Kate Berg
Mr. Ethan Biter
Mr. James Blanco
Mr. Steven Boxer and Ms. Michelle Walker
Ms. Sheri Bronstein
Mr. Sean Callen
Castle Oil Corporation
The Charatan/Holm Family Foundation, Inc.
Chardan Capital Markets
Chef's Warehouse
Mr. and Mrs. Marvin Chudnoff
Cireca Theranostics, LLC
Richard Cohen, Inc.
Mr. and Mrs. Jeffrey Cole
Ms. Christina DeSimone
Ms. Ellen L. Diamond
Ms. Amelia Doggwiler
Mr. and Mrs. Brad Egna
Mrs. Maria E. English-Christensen
Dr. and Mrs. Bob Federman
Stefanie and Paul Feidelson
Mr. Bradley Fishel
Mr. Adam Foster
Ms. Nelsa Gidney
Mr. and Mrs. Robert J. Goldstein
Ms. Lucia Hwong Gordon
Grandstand Sports and Memorabilia, Inc.
The Greenwald Family
Merri and Barry Grieff
Dr. Samuel Guillory
Gullo Specialty Foods
Jane and Lowen Hankin
Mr. Jon Hansburg
Mr. and Mrs. Robert Harrison
Mr. and Mrs. Howard Haykin
Mr. S. Stanley Herman
Sandy and John Horvitz

Mr. James Iorio
Mr. and Mrs. Bill Joseph
Mr. Laurence J. Kirschbaum
Ms. Karen Klopp
Mr. and Mrs. Matthew Knopman
Mr. Steven P. Kornblatt
Mr. Morris Kramer
Mr. and Mrs. Jerry Kremer
Mr. and Mrs. Burt Kremsky
Mr. Charles Kurz
La Force & Stevens
Oscar and Lillian Lama
Mr. and Mrs. Shawn P. Landau
Mrs. Brenda J. Lane
Susan and Bob Lane
Mrs. Phyllis Leventhal
Mr. and Mrs. Laurence R. Levy
Jamie Lichtman
Mr. and Mrs. Alan Lieberman
The Loewy Foundation
Mr. Timothy Madden
Carol and Peter Mc Nierney
Mr. Greg McGuffin
Mr. Steve Montemarano
Morgan Stanley Annual Appeal
Mr. Brian Moses
Mr. Erik W. Muller
Mr. Roderick J. Murray
Neisloss Family Foundation
David and Leonore Nichols
Norsic & Sons
Mr. Ryan Oded
Outdoor Solutions Group
Ms. Grace Park
Mr. Allan L. Pashcow
Mr. Dennis B. Poster
Mr. Jawad Rathore
Mr. John Rice
Mr. Kevin J. Richardson
Mr. Paul Ridley
RMS Fashions, Inc.
The Craig & Flori Roberts Foundation
Mr. and Mrs. Eric Rothfeld
Royal Abstract of New York
Mr. and Mrs. Charles Schaffran
Ms. Lauren Sedbon
Ms. Cassandra Seidenfeld and
Mr. Robert Lyster
Mr. and Mrs. Martin Shafiroff
Mr. and Mrs. Jerome Shapiro
The Shikiar Family Foundation
Mr. Richard Siegal
Mr. John Siegal
Mr. and Mrs. Steven Siegel
Mr. Harlan H. Simon
Ms. Lisa Simonsen
Mr. David Smith
Mr. and Mrs. Richard Solomon
Mr. David Spector
Mr. Neal Sroka
Stamford Tent
Mel and Sheila Stecker
Mr. Michael Steffa
Mr. and Mrs. Michael E. Stoll
Mr. Jerry Sunday
Susan Oberg Investments, Ltd.
Mr. Wayne Talsky
Mr. Robert Tarlowe
Mr. Peter Tipograph
Mr. Russell Tipper
Mr. Christopher Tkac
Ms. Sharon M. Tomao
Mr. Howard H. Tomlinson
Ms. Robin Von Bokhorst
Mr. and Mrs. Michael Walmark
Mr. Thomas Watts
Ms. Evelene Wechsler
Mr. and Mrs. Joel Wernick
Mr. and Mrs. Lawrence Wilens
Whispering Bells Foundation
Fan Xing
Kristina and Marshall Younger
Mr. Gary Zecher

GIFTS WERE MADE IN HONOR OR IN MEMORY OF

Mr. Peter Bartlett
Sandy Biber
Brother of Anne Bushinger
Mrs. Dale Claman
Mr. Louis Cochet
Mr. Avi Concool
Ms. Susan Davis
Ms. Signora Germana Donato-Mangiarotti
Ms. Anna Elman
Ms. Ruth Finley
Mr. Robert Fishbein
Mr. Mark J. Fizulich
Mr. Howard Fuss
Chet and Nancy Gilbert
Ms. Blanche Gische
Mr. Larry Goichman
Mr. Abner J. Golieb
Ms. Sylvia Hoffman
Mr. Arthur E. Imperatore, Sr.
Mr. Gary Jacob
Mr. Sandy Kadish
Mr. Bernard Kaminsky
Mr. Irwin Klein
Mr. Herbert Kramer
Mrs. Marcia Lavipour
Elin and Michael Nierenberg
Mr. Joseph R. Paolino, Sr.
Ms. Jessie Pek
Ms. Bernette B. Plump
Ms. Charna Radbell
Mr. Shawn J. Raysor
Ms. Katherine R. Ridley
Ms. Sindy Schurkman Rubenstein
Mr. Charles Schaffran
Ms. Emma Senders
Mr. Mayer Siegel
Mr. Jack Skoog
Mr. David S. Taub
Ms. Kathy Tipper
Mr. Irving Toplin
Ms. Melanie Twomey
Mr. Jack Waxman
Mrs. Marion Waxman
Dr. Samuel Waxman
Ms. Nancy Weintraub

A NOTE TO OUR SUPPORTERS

We have carefully reviewed all gifts made to the Samuel Waxman Cancer Research Foundation to ensure each gift is properly recognized. The Thank You list includes all gifts made between January 1, 2014 and December 31, 2014. Gifts mentioned exclude in-kind donations and multiple year pledges.

We make every effort to follow the donor's preferences when compiling the annual report list. If you would prefer to have your name listed differently in the future, please let us know. If we have made a mistake, we sincerely apologize for our error and ask you to bring it to our attention. Please contact Jay Camp at 646-398-5260 so the record may be corrected. Thank you.

Photo credits:
Gala: Rebecca Weiss Photography and Patrick McMullan
Hampton's Happening: Society-in-Focus
Golf tournament: Jerry Lacay
Scientific Symposium: Andrei Jackamets
Ladies Who Lunch for a Cure: Lin Pernille

FINANCIAL STATEMENT

(July 1, 2013 – June 30, 2014 audited)

REVENUE

Contributions	$245,000
Program Grants	$ 1,466,000
Event Income	$1,211,000
Investment Income	$ 65,000
Total Revenue	**$2,987,000**

EXPENSE

Program Services	$3,241,000
Fundraising	$222,000
Management and General	$556,000
Total Expense	**$4,019,000**

SURPLUS/(DEFICIT) ($1,032,000)

SAMUEL WAXMAN CANCER RESEARCH FOUNDATION

FOUNDATION TEAM

Founder and Chief Executive Officer – Samuel Waxman, M.D.
Chief Scientific Officer – Jonathan Licht, M.D.
Chief Mission Officer – Alan Rosmarin, M.D.
Director of Special Events – Bridget Stein
Director of Marketing and Communications – Edgar Trinidad
Director of Development – Boris Cooper
Database Manager – Jay Camp
Office Manager – Amanda Aronson
Development Coordinator – Erica Linden-Fineberg
Scientific Advisory Board – Steven D. Gore, M.D., Lorraine Gudas, Ph.D., Ramon Parsons, M.D., Ph.D., Nancy Speck, Ph.D., Hua Yu, Ph.D.

FOUNDATION BOARD

Chairman – Michael Nierenberg
President – Robert Kantor
Vice Presidents – Spencer Waxman, Dena K. Weiner
Treasurer – Thomas A. Conway
Secretary – Laurie L. Schaffran
Board of Directors – Dale Claman, Kenneth Fishel, James E. Frankel, Gary Gladstein, Clifford Greenberg, Dennis A. Herman, Linda Herman, David Hinkelman, Alissa Jacob, Gary Jacob, Howard Kurz, Matthew Lyons, Riva Ariella Ritvo-Slifka, Howard Shlafmitz, Tony M. Shogren, Baron Silverstein, David S. Taub+, Samuel Waxman, M.D.
Honorary Board – Maureen Cogan, Martin L. Coyne, Mary Kantor, Abner Levine +, Mildred Levine, Susan W. Rose, Alan P. Safir *, Joan A. Safir *, Edwin C. Scheurer +, Alfred J. Seaman + , Zena Wiener
Chairman's Council – Lawrence Altman, Peter Claman, Ruth Finley, Arminio Fraga, Betsey Johnson, Costas Kondylis, Thomas Marano, J. Jay Mautner, Tadashi Shoji, Bernard Sillins

*** Past Chair + Deceased**

420 LEXINGTON AVE. SUITE 825
NEW YORK, NY 10170

TEL: 212-867-4502
SWCRF@WAXMANCANCER.ORG
WAXMANCANCER.ORG